Learn more about how the Prolaris® prostate cancer (PCa) prognostic test aligns with the widely cited and accepted Simon et al. evidentiary framework of 2009, positioning it for favorable payer coverage decisions. Analysis across six published studies with non-overlapping patient cohorts showing notably consistent and significant results places Prolaris firmly within LOE II – which stands as a practical, real-world benchmark for clinical utility for a disease with a long natural history and that is regularly over treated.

Click here to read the white paper.